UPDATED: Gilead ? Pivotal Covid-19 study of remdesivir ?met its primary endpoint?

Gilead has declared a huge victory in the war against Covid-19. In a short statement, the big biotech said that the pivotal, controlled study of remdesivir at the National Institute of Allergy and Infectious Diseases had met its primary endpoint. This was one of the key clinical hurdles set up…

Click to view original post